The acquisition of the Hanau production site for pharmaceutical ingredients is meant to complement ProChem’s capabilities in chemical production and analytics.
The CDMO is moving its corporate headquarters from San Diego to Blue Ash, Ohio, and adding a multi-purpose injectable fill-finish line at its West Chester facility.
The Bohumil site will initially produce supportive proteins for next-generation diabetes and obesity medicines as part of Novo Nordisk’s global manufacturing network.
The inspection supported EU marketing authorization applications for 19 biologics spanning antibodies, enzymes and fusion proteins from 13 clients, according to company.
The tool is designed to analyze the CDMO’s data to accelerate root cause analysis and corrective action development for deviations and complaints across its network.
The new Florida facility enables coordinated supply of critical in vitro transcription materials from research through commercial-scale RNA therapeutic production.
The plant adds 100 cubic meters of reactor capacity for complex, high-containment drug substance production to bolster the CDMO’s small molecule services.
The investment at Eisai’s Hatfield facility will add cold-chain packaging and logistics capabilities for injectable medicines, including Alzheimer’s therapy lecanemab.
The funding will support the next phase of the company’s global “smart factory” buildout, which includes a manufacturing facility under construction in the Netherlands.
The multi-million-dollar investment expands the CDMO’s sterile manufacturing footprint and is meant to increase capacity to support biologics and advanced therapies.
The funding will support pipeline expansion across biosimilars, innovative medicines, and animal health, as well as development of proprietary rapid-production technologies.
The in-house capability supports an integrated path from DNA to IND submission, eliminating external handoffs for biologics developers, according to the company.
The platform reportedly features a pull-push mechanism designed to reduce dosing errors and supports delivery volumes up to 0.75 mL for use with standard cartridges.
The two Irish beta-lactam antibiotic manufacturers have aligned administrative systems, supply chains, and business operations as Phase 2 process optimization gets underway.
The collaboration covers tech transfer, master virus seed manufacturing, and GMP clinical material production for Fusix’s lead candidate ahead of first-in-human trials.
The 30,000-square-meter facility is designed to produce approximately 100 million units of pre-filled syringes and vials annually when operations begin in 2027.
The new facility expands peptide API manufacturing capabilities for process scale-up, purification, and lyophilization supporting global drug development programs.
The Lebanon facility’s new production lines add domestic capacity for ready-to-use and specialty vials to support biologics, vaccines, and emergency drug supply resilience.
The updated program delivers toxicology-grade drug substance in approximately two months and IND readiness in up to six months, supported by a new vector technology platform.
The 3,500-square-meter facility adds 20 independent cGMP production lines for cell therapies, including CAR-T, and is expected to begin operations in Q3 of 2026.
UNICEF's dual-hemisphere immunization programs delivering 640,000 doses will support year-round utilization of SK bioscience’s manufacturing facilities.
The expanded agreement adds a second U.S. manufacturing site and larger batch production capabilities to support later-stage clinical trials of Ratio’s radiotherapeutic.